Welcome to our dedicated page for Rapid Micro Biosystems SEC filings (Ticker: RPID), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rapid Micro Biosystems, Inc. filings document the company's microbial quality-control automation business, governance matters and capital structure. Form 8-K reports furnish operating results, preliminary revenue updates, Regulation FD disclosures about the Growth Direct platform, and material agreements such as term-loan financing secured by company assets and related warrants for Class A common stock.
Proxy filings cover annual meeting procedures, stockholder voting matters, board governance and executive compensation disclosures. Other material-event reports address officer-transition and compensatory-arrangement disclosures, while recent cover pages identify the company as an emerging growth company for Exchange Act reporting purposes.
RPID filed a Rule 144 notice for the proposed sale of 5,000 Class A shares dated 06/10/2026. The filing lists the method as a Stock Option Exercise with cash proceeds to the issuer. The filing also reports a prior sale of 9,603 Class A shares on 03/11/2026 for $41,466.71. Shares outstanding were 41,669,673 as of 06/10/2026.
Rapid Micro Biosystems director Inese Lowenstein increased her stake through a combined share purchase and warrant grant. On May 29, 2026, she acquired 12,787 shares of Class A Common Stock at $1.955 per share in a registered direct offering, together with Series A and Series B Warrants to purchase 12,787 shares each. The Series A Warrant has a $1.955 exercise price and expires on May 29, 2027, while the Series B Warrant has a $2.34 exercise price and expires on May 29, 2031. After this transaction, she directly holds 70,687 Class A shares. The warrants are subject to a 4.99% beneficial ownership cap that restricts exercises that would push her above that ownership level.
RAPID MICRO BIOSYSTEMS director Melinda Litherland increased her stake through a registered direct offering. She purchased 12,787 shares of Class A Common Stock at $1.955 per share and received accompanying Series A and Series B warrants to buy 12,787 shares each.
Following the transaction, she holds 100,687 Class A shares directly. The Series A warrant has a $1.955 exercise price and expires on May 29, 2027, while the Series B warrant has a $2.34 exercise price and expires on May 29, 2031. Both warrants become exercisable on November 29, 2026 and include a 4.99% beneficial ownership cap.
Rapid Micro Biosystems director Kirk Malloy increased his stake through a registered direct offering. On May 29, 2026, he purchased 12,787 shares of Class A Common Stock together with an accompanying Series A Warrant and Series B Warrant, each to buy 12,787 additional shares, for a combined purchase price of $1.955 per share plus both warrants.
Following the transactions, Malloy holds 60,687 shares directly and 10,000 shares indirectly through a family trust. The Series A Warrant is exercisable at $1.955 per share from November 29, 2026 until May 29, 2027, and the Series B Warrant at $2.340 per share from November 29, 2026 until May 29, 2031. Both warrants include a 4.99% beneficial ownership cap on exercise.
RAPID MICRO BIOSYSTEMS, INC. Chief Financial Officer Sean M. Wirtjes acquired 12,787 shares of Class A Common Stock in a registered direct offering at $1.955 per share, together with accompanying Series A and Series B warrants for 12,787 shares each.
The Series A Warrant has a $1.955 exercise price and expires on May 29, 2027, while the Series B Warrant has a $2.340 exercise price and expires on May 29, 2031. After these awards, he directly holds 568,981 shares of Class A Common Stock and 12,787 Series A and 12,787 Series B warrants. Both warrant series are subject to a 4.99% beneficial ownership cap on exercise.
RAPID MICRO BIOSYSTEMS, INC. President and CEO Robert G. Spignesi Jr. reported acquiring 12,787 shares of Class A Common Stock at $1.955 per share in a registered direct offering. With this grant and prior holdings, he now directly owns 1,190,571 shares of Class A Common Stock.
He also received a Series A Warrant and a Series B Warrant, each covering 12,787 shares of Class A Common Stock. The Series A Warrant has an exercise price of $1.955 and expires on May 29, 2027, while the Series B Warrant has an exercise price of $2.34 and expires on May 29, 2031. Both warrants are subject to a 9.99% beneficial ownership cap, limiting exercises that would push total beneficial ownership above that threshold.
Rapid Micro Biosystems, Inc. reported the results of its annual meeting of stockholders held on May 21, 2026. There were 41,267,511 Class A common shares eligible to vote, and 37,099,555 shares were represented in person or by proxy, establishing a quorum.
Stockholders elected Richard Kollender as a Class II director to serve until the 2029 annual meeting, with 23,180,585 votes for, 1,998,525 votes withheld, and 11,920,445 broker non-votes. Stockholders also ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 37,096,030 votes for, 3,292 against, 233 abstentions, and no broker non-votes.
RAPID MICRO BIOSYSTEMS, INC. director Kirk Malloy reported equity compensation awards on Class A Common Stock. He received 19,300 restricted stock units (RSUs) at no cash cost, increasing his directly held common shares to 47,900 after the award.
He was also granted a stock option for 38,700 shares of Class A Common Stock with an exercise price of $2.0700 per share, expiring on May 20, 2036. Both the RSUs and the option vest in full on the earlier of the first anniversary of the grant date or immediately before the next annual stockholders’ meeting, if he remains in continuous service. In addition, an indirect holding of 10,000 shares is reported in a family trust where he shares investment power.
RAPID MICRO BIOSYSTEMS, INC. director Inese Lowenstein reported new equity compensation awards. She received 19,300 shares of Class A common stock as restricted stock units that vest in full on the earlier of the first anniversary of the grant date or the day immediately prior to the next annual stockholder meeting, provided she remains in continuous service.
She was also granted a stock option for 38,700 shares of Class A common stock at an exercise price of $2.07 per share, with the option vesting on the same schedule. After the grant, she directly holds 57,900 shares of Class A common stock and 38,700 options.
RAPID MICRO BIOSYSTEMS, INC. director Melinda Litherland received equity-based compensation consisting of restricted stock units and stock options.
She was granted 19,300 shares of Class A Common Stock as restricted stock units that vest in full on the earlier of the first anniversary of the grant date or the day immediately before the next annual stockholder meeting, if she remains in continuous service.
She was also granted options on 38,700 shares of Class A Common Stock at an exercise price of $2.07 per share, which vest on the same schedule and expire on May 20, 2036. Following these grants, she directly owns 87,900 shares of Class A Common Stock.